- Home
- CNF vs SNTI Comparison
CNF vs SNTI Comparison
Compare CNF & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- SNTI
- Stock Information
- Founded
- CNF 1999
- SNTI 2016
- Country
- CNF China
- SNTI United States
- Employees
- CNF N/A
- SNTI N/A
- Industry
- CNF Finance: Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- SNTI Health Care
- Exchange
- CNF Nasdaq
- SNTI Nasdaq
- Market Cap
- CNF 35.7M
- SNTI 39.6M
- IPO Year
- CNF 2018
- SNTI N/A
- Fundamental
- Price
- CNF $3.05
- SNTI $1.36
- Analyst Decision
- CNF
- SNTI Strong Buy
- Analyst Count
- CNF 0
- SNTI 2
- Target Price
- CNF N/A
- SNTI $8.50
- AVG Volume (30 Days)
- CNF 97.1K
- SNTI 124.8K
- Earning Date
- CNF 08-28-2025
- SNTI 11-13-2025
- Dividend Yield
- CNF N/A
- SNTI N/A
- EPS Growth
- CNF N/A
- SNTI N/A
- EPS
- CNF N/A
- SNTI N/A
- Revenue
- CNF $50,241,013.00
- SNTI N/A
- Revenue This Year
- CNF $252.34
- SNTI N/A
- Revenue Next Year
- CNF N/A
- SNTI $150.00
- P/E Ratio
- CNF N/A
- SNTI N/A
- Revenue Growth
- CNF N/A
- SNTI N/A
- 52 Week Low
- CNF $2.36
- SNTI $1.26
- 52 Week High
- CNF $28.40
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CNF 37.38
- SNTI 33.66
- Support Level
- CNF $2.85
- SNTI $1.38
- Resistance Level
- CNF $3.59
- SNTI $1.39
- Average True Range (ATR)
- CNF 0.95
- SNTI 0.08
- MACD
- CNF -0.02
- SNTI 0.01
- Stochastic Oscillator
- CNF 17.74
- SNTI 25.71
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.